lung cancer are treated with surgery, which is followed by adjuvant chemotherapy in stage II and IIIA patients. Neoadjuvant chemotherapy in early-stage lung cancer has been evaluated in many ... neoadjuvant chemotherapy…
encompass current strategies used in recent clinical trials of NSCLC. Encouraging results of Phase II trials in antigen-specific immunotherapy have led to three subsequent Phase III trials, which
occurs almost exclusively in patients without mutations in K-ras or EGFR. Completed Phase I and II trials suggest significant clinical activity of an ALK kinase inhibitor, PF‑02341066 (crizotinib
treatment. The excellent bactericidal activity data has been confirmed in animal models and Phase II studies. Animal experiments suggest that by using moxifloxacin to replace either ethambutol or isoniazid
novel first-in-class anticancer quinolone derivative that intercalates DNA and inhibits topoisomerase II. Vosaroxin was shown in preclinical studies to be a potent antileukemia agent with unique features that ... single…
does not induce cell death of tumor B cells by apoptosis. In a Phase I/II study, ofatumumab demonstrated significant depletion of CD19+/CD5+ CLL cells, and showed a favorable
associated with the induction of autophagy. SFN is known to induce phase II antioxidant genes via Nrf2 activation, which regulates ROS levels and stimulates autophagy in prostate cancer cells. Mechanistically
factors: systolic blood pressure is reduced by 2–6 mmHg with liraglutide treatment, while Phase II studies have demonstrated improvements in molecular markers of cardiovascular risk. Treatment with liraglutide also
Hunter syndrome (mucopolysaccharidosis II) is a rare, X-linked disorder caused by the missing or deficient lysosomal enzyme, iduronate-2-sulfatase, which leads to tissue and organ accumulation of glycosaminoglycans…
target the glomerular basement membrane and have been shown to reduce albuminuria in multiple Phase II clinical trials. Inhibitors of advanced glycation end-product formation (e.g., pyridoxamine) reduce the renal…
shown promise at increasing time to progression with little or no associated toxicity in Phase II studies. The drug is specifically designed to induce tolerance in patients with HLA types ... large Phase III secondary…
chosen and the type of design. The opportunity for more novel designs resides in Phase II studies, and several types of novel designs are discussed, including: adaptive designs, Bayesian designs
antibody with high affinity for soluble and cell-surface transmembrane TNF-α. Results from Phase II and III trials and long-term studies with continuous and intermittent maintenance regimens indicate
administered agent with properties of substrate synthesis inhibition and an acceptable pharmacokinetic profile. In Phase II clinical trials (both in the published pivotal and extension phase), eliglustat was shown
Lower doses are probably required for patients with creatinine clearance <30 ml/min. In Phase II and III randomized-controlled trials, dalbavancin was as effective as comparator antibiotics
dilution of matrix can eliminate the need of matrix standards in LC-MS/MS (ii) the commodities can be grouped together, thus reducing the number of matrices needed to make ... were studied by comparing of slopes of…
development of initial package, in-depth interviews and, consultations with experts and stakeholders. Phase II (intervention) was a quasi-experimental study which involved pre-post intervention (6 months of weight
using male albino mice. Anti-infl ammatory activity was determined by formalin test (Phase II). Seven groups of mice were used. Group 1 control group (1% T80); group 2: treated ... pain (hot plate and formalin test…
vitro. One of the first of these agents, vandetanib, has been evaluated in international Phase II and III clinical trials. In 2011, vandetanib became the first agent approved
highly melanotic; bilateral sentinel node biopsy was negative. She entered into a randomized Phase II/III clinical study comparing a vaccine composed of irradiated melanoma cells plus BCG plus GMCSF
cyclodextrins as a solubilizing tool for their stubborn like bricks APIs (BCS class II and IV)). The reason is obvious: Easy to scale up and a successful presence, of both ... centered on a coherent approach of…
impact of these events, and the commonly used MRI end points used in Phase II studies have a complex relationship with both events and permanent neurological disability. Current designs favor ... randomized…
including everolimus – target the mTOR signaling cascade, inhibit cell proliferation and evoke apoptosis. Recent Phase II and III clinical trials demonstrated that everolimus is effective in advanced pNETs
motor symptoms, with fewer side effects than the treatment options currently available. In a Phase II and III study, pridopidine significantly improved motor functions in Huntington patients with an adverse
preclinical data showing efficacy in preinvasive cancer, cancer stem cells and metastatic cancer. Phase I/II clinical trials are providing safety and efficacy data regarding CQ or HCQ monotherapy
For authors and organisers
Publish, present and keep up with your field
Find the right journal for your paper and submit your manuscript.